Phase I Clinical Trials

• CT179 · PDF SON-1010（IL12-F H AB）与曲贝替定在晚期软组织肉瘤中协同增效 SON-1010 (IL12-F H AB) synergizes with trabectedin in advanced soft-tissue sarcoma Sant Chawla, Victoria Chua, Neal Chawla, Erlinda M. Gordon, John Cini, Richard Kenney
• CT180 · PDF 普特利单抗联合标准化疗方案用于中危或高危儿童横纹肌肉瘤患者术前治疗的安全性和疗效：一项I/II期研究 Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the preoperative treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study Yi Que, Suying Lu, Feifei Sun, Juan Wang, Junting Huang, Jia Zhu, Yu Zhang, Mengjia Song, Zijun Zhen, Yizhuo Zhang
• CT182 · PDF Camu camu联合nivolumab/ipilimumab(N/I)作为转移性肾细胞癌(mRCC)一线治疗：一项随机I期临床试验 Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial Regina Barragan Carrillo, Miguel Zugman, Bertrand Routy, Mallia Geiger, Xiaochen Li, Nazli Dizman, Hedyeh Ebrahimi, Salvador Jaime-Casas, Nicholas Salgia, Joann Hsu, Daniela V. Castro, Benjamin D. Mercier, Koral Sha, Sreya Duttagupta, Tanya B. Dorff, Neal S. Chawla, Ruchi Agarawal, Ekta Kapoor, Marcin Kortylewski, Alex Chehrazi-Raffle, Arielle Elkrief, Sumanta K. Pal
• CT183 · PDF 一种新型经CD55和FcRn生物筛选的RNA溶瘤病毒IVX037联合sintilimab(抗PD-1)治疗晚期微卫星稳定型结直肠癌的Ib期临床评估 Phase Ib clinical evaluation of a novel CD55- and FcRn-bioselected RNA oncolytic virus, IVX037, combined with sintilimab (anti-PD-1) in advanced microsatellite-stable colorectal cancer Jia Liu, Sophia Frentzas, Ganessan Kichenadasse, Timothy Price, Niall Tebbutt, Shehara Mendis, Rafid Al-Asady, Eugene Hsu, Mei Chan, Phillip Tran, Darren Shafren, Oksana Zdanska, Mark Wong
• CT184 · PDF botensilimab(BOT)与balstilimab(BAL)一线优化治疗无肝、骨或脑转移的微卫星稳定型结直肠癌(MSS CRC)的初步结果(BBOpCo) Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsatellite stable colorectal cancer (MSS CRC) without liver, bone, or brain metastasis (BBOpCo) Nicholas C. Devito, Emily Bolch, Aman Opneja, Hope Uronis, Lisa Vlastelica, Gerard C. Blobe, John W. Hickey, Yuexi Kylee Li, Kevin S. Tanager, Cheryl H. Chang, Jingchen Chai, Kara Bonneau, Niharika B. Mettu, Michael A. Morse, Tucker W. Coston, Shiaowen David Hsu, Carol A. Wiggs, Donna Niedzwiecki, Dana A. Warren, John H. Strickler
• CT185 CT185 M3814(peposertib)联合镥177 DOTATATE治疗转移性高分化生长抑素受体阳性胃肠胰神经内分泌肿瘤(GEP-NET)的1期临床试验 A phase 1 trial of M3814 (peposertib) in combination with lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Aman Chauhan, Susanne Arnold, Donglin Yan, Rani Jayswal, Vineeth Sukrithan, Daneng Li, Riham Khouli, Heliosa Soares, Jan Beumer, Steven Gore, Lorraine Pelosof, Elise Kohn, William Carson, Anthony Lowell
• CT186 · PDF 接受nab-紫杉醇、吉西他滨和cobicistat治疗的胰腺癌患者中6-OH-紫杉醇暴露增加相关的肺毒性：IntenSify试验结果 Pulmonary toxicity associated with increased 6-OH-paclitaxel exposure in pancreatic cancer patients treated with nab-paclitaxel, gemcitabine and cobicistat: Results of the IntenSify trial Nicolas Hohmann, Martin R. Sprick, Marietta Kirchner, Lucian Le Cornet, Azaz Ahmed, Markus Kratzmann, Joge-Jossy Tonison, Jacek Stermann, Amina Cheikh Rouhou, Karen Steindorf, Stefan Delorme, Heinz-Peter Schlemmer, David Czock, Jürgen Burhenne, Jacek Hajda, Jens T. Siveke, Thomas Seufferlein, Albrecht Stenzinger, Guy Ungerechts, Dirk Jäger, Andreas Trumpp, Christoph Springfeld
• CT187 · PDF 治疗性HPV16特异性癌症疫苗abipapogene suvaplasmid(VB10.16)联合pembrolizumab作为HPV16+ PD-L1+复发/转移性口咽癌一线治疗的免疫原性：VB-C-03试验1期的初步结果 Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: Preliminary results from phase 1 of the VB-C-03 trial Caroline Even, Saira Khalique, Marc B. Oliva, Marie Vinches, Marta G. Arnau, Kaja C. G. Berg, Ingvild S. Leikfoss, Aleksandra Urban, Marthe J. Jørgensen, Christian W. Wold, Judith Wong, Miriam Ragle Aure, Lena Finnesand, Roberto Oliveri, Agnete B. Fredriksen, Åse Bratland
• CT188 · PDF 瘤内PD-1阻断用于口腔癌预防：同类首创1期临床试验 Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial Moran Amit, Robert Saddawi-Konefka, Shorook Naara, Fred Netto, Fred Netto, Chen F Fushun, Yen Vu, Sophie Li, Tongxin Xie, Shamima Akhter, Hinduja Sathishkumar, Tieling Zhou, Sreyashi Basu, Luana Sousa, Neal Akhave, Theresa Hofstede, Ann Gillenwater, Ed Diaz, Kirsten Pytynia, Lorena Gomez, Michelle Williams, Andrew Sikora, Jeffrey Myers, Humam Kadara, James Allison, Sharma Padmaneee, Mark Chambers
• CT189 · PDF ZL-1310(一种DLL3靶向ADC)治疗神经内分泌癌及其他选定实体瘤患者的1b/2期、开放标签、多中心研究的初步结果 Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors Rohit Thummalapalli, Ming Lu, Alexander Spira, Amr Mohamed, Rahul Aggarwal, Yu Wang, Namrata Vijayvergia, Jordi Rodon, Andrew Scott Paulson, Pingkuan Zhang, Hui Yang, Yuan Xin, Jingmin Wen, Jie Chen
• CT190 · PDF Brexu-cel + 达沙替尼：brexucabtagene autoleucel 后给予达沙替尼脉冲以调节 CAR T 细胞活性用于复发/难治性 B 细胞急性淋巴细胞白血病的安全性与可行性 Brexu-cel + dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia Nikeshan Jeyakumar, Parveen Shiraz, Evan Weber, Alyssa Kanegai, Caroline Wagner, Arvind Ramakrishnan, Bita Sahaf, Matthew Frank, Saurabh Dahiya, Melody Smith, Surbhi Sidana, Crystal Mackall, David Miklos, Lori Muffly
• CT191 · PDF ruxolitinib 与 CDK4/6 抑制剂 abemaciclib 联合在既往接受过治疗的骨髓纤维化患者中显示出安全性和疗效：一项 I 期研究的结果 The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of a Phase I study Jan Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Guiliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Prithviraj Bose, Omar Abdel-Wahab, Ross Levine, Raajit Rampal
• CT192 · PDF 首例接受 LP-118（一种新型 Bcl-2/Bcl-xL 双重抑制剂）治疗的实体瘤患者报告 The first report of patients with solid tumors treated with LP-118, a novel Bcl-2/Bcl-xL dual inhibitor Qing Zhou, Xiaorong Dong, Jianya Zhou, Duidui Hong, Yue Shen, Fenlai Tan, Xiang Xiao, Yejiang Lou, Jiemin Xie, Yilong Wu
• CT193 · PDF ZL-1310（一种 DLL3 靶向 ADC）在既往接受过治疗且有基线脑转移的广泛期小细胞肺癌患者中的颅内活性：一项 1 期试验的分析 Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial Pedro Rocha, Manish Patel, Yi-Long Wu, Jun Zhao, Grace Dy, María Eugenia Olmedo García, Qiming Wang, Valentina Gambardella, Oscar Juan-Vidal, Afshin Dowlati, David Vicente Baz, Alexander Spira, Anne C. Chiang, Yingying Du, Martin Gutierrez, Xiaorong Dong, Jie Hu, Mariam Alexander, Haiyong Wang, Wenxiu Yao, Liza Villaruz, Zhen Wang, Pingkuan Zhang, Renke Zhou, Xiao Wang, Luis Paz-Ares
• CT194 · PDF 在葡萄膜黑色素瘤伴肝转移患者中通过肝动脉输注局部给予肿瘤浸润淋巴细胞 Local administration of tumor infiltrating lymphocytes by hepatic artery infusion in patients with uveal melanoma and liver metastases Axel Nelson, Rebecca Riise, Samuel Alsen, Andrew Wong, Per Carlsson, Sebastian Edman, Jan Holgersson, Roger Olofsson Bagge, Iva Johansson, May Sadik, Lars Edenbrandt, Lisa M. Nilsson, Jonas A. Nilsson, Lars Ny
• CT195 · PDF 快速制造、低 IL-2 依赖的 FAST-TIL 用于治疗亚洲晚期黑色素瘤患者：一项 I 期临床试验的中位 6 个月随访数据 Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial Di Wu, Yuan Fang, Zhen Guo, Jie Liu, Jing Lin, Yaotiao Deng, Shijie Lan, Shuhang Wang, Ganchen Gao, Pengxiang Wang, Xinhua Zhang, Yi Zhao, Yu Chen, Yu Jiang, Ning Li
• CT197 · PDF ERY974 在磷脂酰肌醇蛋白聚糖-3（GPC-3）阳性晚期实体瘤患者中的 I 期研究 Phase I study of ERY974 in patients with glypican-3 (GPC-3)-positive advanced solid tumors Haruyasu Murakami, Hidetoshi Hayashi, Kensei Yamagushi, Kei Muro, Taroh Satoh, Tomohiro Nishina, Eisuke Ueda, Chika Ogami, Hitomi Takeshita, Hayato Takahashi, Mikiko Nakamura, Mihiro Toba, Yasutoshi Kuboki
• CT198 · PDF 一种一流的抗 miRNA（antagomir）疗法治疗晚期实体瘤的 1 期临床试验 Phase 1 clinical trial of a first-in-class antagomir therapeutic against advanced solid tumors Zdravka Medarova, Siqing Fu, William McKean, Minal Barve, Alex Spira, Daniel Vlock, Lisa Fortin, Susan Duggan
• CT199 · PDF SAR445877：一种PD-1靶向的IL-15突变蛋白，可选择性激活PD-1+ T细胞，在临床前小鼠模型和早期人体临床试验中均展现出治疗活性 SAR445877: A PD-1-targeted IL-15 mutein selectively activates PD-1+ T cells resulting in therapeutic activity across pre-clinical mouse models and in early human clinical trials Isaraphorn Pratumchai, Marie Bernardo, Julien Tessier, Fatima Menas, Jaroslav Zak, Kristi L. Marquardt, Joon Sang Lee, AHyun Choi, Anthony M. Byers, Mikielia Devonish, Roberto Carrio, Dan Lu, Stella Martomo, Jeegar Patel, Yu-an Zhang, Ingeborg Langohr, Virna Cortez-Retamozo, Dinesh S. Bangari, Angela Hadjipanayis, Xiangming Li, John R. Teijaro, Valeria R. Fantin, Raymond P. Perez, Donald R. Shaffer
• CT200 · PDF ENPP1抑制剂vizenpistat治疗实体瘤的I期剂量递增研究 Phase I dose-escalation study of ENPP1 inhibitor, vizenpistat, for the treatment of solid tumors Mohan R. Kaadige, Alexis S. Larsen, Trason Thode, Margaux Steinbach, Scott Houston, Srinivas Kasibhatla, Jonathan Northrup, Sunil Sharma

在会议检索中浏览本分会场